ONCOMED PHARMACEUTICALS INC's ticker is OMED and the CUSIP is 68234X102.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2019 | $40,000 | +42.9% | 38,000 | 0.0% | 0.01% | +16.7% |
| Q4 2018 | $28,000 | -65.4% | 38,000 | 0.0% | 0.01% | -57.1% |
| Q3 2018 | $81,000 | -8.0% | 38,000 | 0.0% | 0.01% | -12.5% |
| Q2 2018 | $88,000 | -27.3% | 38,000 | 0.0% | 0.02% | -27.3% |
| Q1 2018 | $121,000 | -22.4% | 38,000 | 0.0% | 0.02% | -18.5% |
| Q4 2017 | $156,000 | -9.3% | 38,000 | 0.0% | 0.03% | -12.9% |
| Q3 2017 | $172,000 | +7.5% | 38,000 | -20.8% | 0.03% | +3.3% |
| Q2 2017 | $160,000 | -63.8% | 48,000 | 0.0% | 0.03% | -64.3% |
| Q1 2017 | $442,000 | -18.1% | 48,000 | -31.4% | 0.08% | -21.5% |
| Q4 2016 | $540,000 | -32.5% | 70,000 | 0.0% | 0.11% | -35.5% |
| Q3 2016 | $800,000 | -7.2% | 70,000 | 0.0% | 0.17% | -9.3% |
| Q2 2016 | $862,000 | +9.9% | 70,000 | 0.0% | 0.18% | +9.6% |
| Q1 2016 | $784,000 | -50.3% | 70,000 | 0.0% | 0.17% | -48.5% |
| Q4 2015 | $1,578,000 | – | 70,000 | – | 0.32% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BVF INC/IL | 4,108,815 | $4,273,000 | 0.48% |
| Birchview Capital, LP | 372,557 | $387,000 | 0.24% |
| Perceptive Advisors | 1,719,111 | $1,787,000 | 0.05% |
| Fondren Management LP | 25,136 | $26,000 | 0.02% |
| Cannell & Co. | 281,983 | $293,000 | 0.01% |
| APPLETON PARTNERS INC/MA | 66,206 | $69,000 | 0.01% |
| Quinn Opportunity Partners LLC | 66,162 | $69,000 | 0.01% |
| NJ State Employees Deferred Compensation Plan | 38,000 | $40,000 | 0.01% |
| Candriam S.C.A. | 380,000 | $395,000 | 0.01% |
| PRIMECAP MANAGEMENT CO/CA/ | 5,451,400 | $5,669,000 | 0.00% |